A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
05/2011
05/18/2011	EP2321317A1 Fused pyrrolidino-cyclopropane derivatives as selective 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors
05/18/2011	EP2321316A1 Substituted pyrimidin-4-one derivatives
05/18/2011	EP2321315A2 Substituted alkyl pyrimidin-4-one derivatives
05/18/2011	EP2321314A2 Substituted pyrimidone derivatives
05/18/2011	EP2321313A1 Substituted pyrimido [2, 1-a]isoquinolin-4-one derivatives
05/18/2011	EP2321309A1 Benzothiazoles and aza-analogues thereof use as antibacterial agents
05/18/2011	EP2321308A1 Piperidine gpcr agonists
05/18/2011	EP2321307A1 Tricyclic alkylaminomethyloxazolidinone derivatives
05/18/2011	EP2321306A1 3-cyanopyrrolidinyl-phenyl-oxazolidinones as antibacterial agents
05/18/2011	EP2321305A1 Heterocyclic gpcr agonists
05/18/2011	EP2321304A2 Therapeutic beta-lactams
05/18/2011	EP2321303A2 Compounds that modulate intracellular calcium
05/18/2011	EP2321302A2 Azacitidine process and polymorphs
05/18/2011	EP2321301A1 New heterocyclic carboxamides for use as thrombin inhibitors
05/18/2011	EP2321300A1 Chlorophyll catabolites
05/18/2011	EP2321299A2 Pyridons as pdk1 inhibitors
05/18/2011	EP2321298A2 Aurora kinase modulators and methods of use
05/18/2011	EP2321297A1 Piperidinyl gpcr agonists
05/18/2011	EP2321296A1 Substituted 5-aminopyrazoles and use thereof
05/18/2011	EP2321295A2 4-(pyridin-4-yl)-1h-[1,3,5]triazin-2-one derivatives as gsk3-beta inhibitors for the treatment of neurodegenerative diseases
05/18/2011	EP2321289A1 Selective glycosidase inhibitors and uses thereof
05/18/2011	EP2321288A1 Oxazole derivatives useful as inhibitors of faah
05/18/2011	EP2321287A1 4,5-dihydro-oxazol-2-yl derivatives
05/18/2011	EP2321286A1 Substituted n-oxide pyrazine derivatives
05/18/2011	EP2321285A1 Diazepan and piperazine derivatives modulators of chemokine receptors
05/18/2011	EP2321284A1 Sulfone substituted quinazoline derivatives as immune-modulators for the treatment of inflammatory and allergic diseases
05/18/2011	EP2321283A1 2, 6-diamino-pyrimidin- 5-yl-carboxamides as syk or jak kinases inhibitors
05/18/2011	EP2321282A1 New benzimidazole derivatives
05/18/2011	EP2321281A2 Anti inflammatory compounds
05/18/2011	EP2321279A1 Daa-pyridine as peripheral benzodiazepine receptor ligand for diagnostic imaging and pharmaceutical treatment
05/18/2011	EP2321278A2 PYRIDINYL MODULATORS OF y-SECRETASE
05/18/2011	EP2321276A1 New compounds vii
05/18/2011	EP2321275A1 Anti-malarial compounds
05/18/2011	EP2321272A1 Organic compounds
05/18/2011	EP2321271A1 Organosulfur compounds, a method of making organosulfur compounds and their use for inhibiting the growth of tumour cells
05/18/2011	EP2321268A2 Bi-aryl aminotetralines
05/18/2011	EP2321267A2 Monoaryl aminotetralines
05/18/2011	EP2321266A2 Substituted aminotetralines
05/18/2011	EP2321265A1 Inositol and trehalose derivatives and pharmaceutical compositions for treating neurodegenerative diseases comprising the same
05/18/2011	EP2321264A2 Deacetylase inhibitors and uses thereof
05/18/2011	EP2321259A2 New compounds for the treatment of cancer
05/18/2011	EP2321258A1 Polymorphic form of rasagiline mesylate
05/18/2011	EP2321249A1 Salts of tramadol and ibuprofen and their crystal form in the treatment of pain
05/18/2011	EP2321012A1 Organoarsenic compounds and methods for the treatment of cancer
05/18/2011	EP2321011A1 Diaryl compounds and uses thereof
05/18/2011	EP2320949A2 Omega-3 enriched fish oil-in-water parenteral nutrition emulsions
05/18/2011	EP2320948A1 Methods for treating reperfusion injuries
05/18/2011	EP2320947A2 Alpha-galactosyl ceramide analogs and their use as immunotherapies, adjuvants, and intiviral, antibacterial, and anticancer agents
05/18/2011	EP2320925A2 Complement antagonists and uses thereof
05/18/2011	EP2320921A1 Compositions comprising tea tree oil and methods for the prevention and treatment of cancer
05/18/2011	EP2320920A2 Topical anti-inflammatory combination
05/18/2011	EP2320916A2 Antihistamine and antihistamine-like nasal application, products, and method
05/18/2011	EP2320915A1 Gentle, non-irritating, non-alcohoholic skin disinfectant
05/18/2011	EP2320914A1 Anti-cancer composition comprising microrna molecules
05/18/2011	EP2320913A1 Nucleic acid aptamers
05/18/2011	EP2320912A1 Treatment of retinal degeneration
05/18/2011	EP2320911A1 Vasoconstriction compositions and methods of use
05/18/2011	EP2320910A1 Chemical compounds and uses
05/18/2011	EP2320909A1 Chemical compounds
05/18/2011	EP2320908A1 Chemical compounds
05/18/2011	EP2320907A1 Therapeutic compounds
05/18/2011	EP2320906A1 Heterocyclic amide derivatives as ep4 receptor antagonists
05/18/2011	EP2320905A1 Novel adenine derivatives
05/18/2011	EP2320904A2 Aminopyrimidine inhibitors of histamine receptors for the treatment of disease
05/18/2011	EP2320903A1 THERAPEUTIC COMBINATION COMPRISING A CDKs INHIBITOR AND AN ANTINEOPLASTIC AGENT
05/18/2011	EP2320902A1 Pharmaceutical composition comprising n-ý3-chloro-4-ý(3- fluorophenyl)methoxy¨phenyl¨-6-ý5ýýý2-(methylsulfonyl)ethyl¨amino¨methyl¨-2-furyl¨-4- quinazolinamine
05/18/2011	EP2320901A1 Pharmaceutical composition comprising n-ý3-chloro-4-ý(3- fluorophenyl)methoxy¨phenyl¨-6-ý5ýýý2-(methylsulfonyl)ethyl¨amino¨methyl¨-2-furyl¨-4- quinazolinamine
05/18/2011	EP2320900A1 Use of opioids or opioid mimetics for the treatment of resistant cancer patients
05/18/2011	EP2320899A1 Dihydrotetrabenazine for treatment of asthma
05/18/2011	EP2320898A2 Smoking cessation kit and method
05/18/2011	EP2320897A1 Compositions and methods of treating amyloid disease
05/18/2011	EP2320896A2 Vinpocetine and eburnamonine derivatives for promoting bone growth
05/18/2011	EP2320895A2 Cdk modulators
05/18/2011	EP2320894A1 Chemoprevention of head and neck squamous cell carcinomas
05/18/2011	EP2320893A1 Combination of a triptan and an nsaid
05/18/2011	EP2320892A2 Combination products
05/18/2011	EP2320891A1 Butyrylcholinesterase ligands as diagnostic tools and treatment for deseases of the nervous system
05/18/2011	EP2320890A2 Indication of use of erdosteine as antidote in a large number of intoxications, especially in heavy metals like lead or mercury, and paracetamol
05/18/2011	EP2320889A2 Methods for enhancing energy metabolism
05/18/2011	EP2320888A1 Laidlomycin compositions and methods
05/18/2011	EP2320887A1 Pharmaceutical compositions comprising lignans and their derivatives for treating hyperplastic diseases
05/18/2011	EP2320886A1 Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
05/18/2011	EP2320885A1 Patches and methods for the transdermal delivery of a therapeutically effective amount of iron
05/18/2011	EP2320884A2 Phosphate binding materials and their uses
05/18/2011	EP2320883A1 Compositions and methods for influencing satiety, lipid metabolism, and fat utilization
05/18/2011	EP2320882A1 A synthetic vaccine component
05/18/2011	EP2320881A1 Cannabinoids in combination with non -cannabinoid chemotherapeutic agents (e.g. serm or alkylating agents)
05/18/2011	EP2320880A1 Naphthoquinone derivatives useful for prevention of amyloid deposits and treatment of diseases involving amyloidogenesis
05/18/2011	EP2320879A2 Pharmaceutical composition comprising jasmonates
05/18/2011	EP2320878A1 Monoterpenes for treating respiratory tract diseases, in particular bronchopulmonary diseases
05/18/2011	EP2320874A1 Solid pharmaceutical composition comprising exemestane
05/18/2011	EP2320873A1 Telmisartan tablets
05/18/2011	EP2320871A1 Intravaginal devices with a rigid support, methods of making, and uses thereof
05/18/2011	EP2320740A1 Pharmaceutical compositions and methods for producing low impurity concentrations of the same
05/18/2011	EP2320739A1 Pharmaceutical compositions and methods for stabilizing the same
05/18/2011	EP2320738A1 Substituted aminothiazole derivatives, pharmaceutical compositions, and methods of use
05/18/2011	EP2320737A1 Pyrazoloý1,5-a¨pyridines as mark inhibitors
05/18/2011	EP2320734A1 Flavin derivatives
05/18/2011	EP2320732A2 Substituted imidazole combinations
05/18/2011	EP2320731A1 Methods and compositions for sleep disorders and other disorders

1 ... 1734 1735 1736 1737 1738 1739 1740 1741 1742 1743 1744 1745 1746 1747 1748 1749 1750 1751 1752 1753 1754 ... 7860